| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/22/2022 | -10.4% | JP Morgan | $27 → $28 | Downgrades | Neutral → Underweight |
| 11/03/2022 | -13.6% | JP Morgan | $31.5 → $27 | Maintains | Neutral |
| 10/21/2022 | — | Raymond James | Downgrades | Strong Buy → Market Perform | |
| 08/01/2022 | 40.8% | Raymond James | $77 → $44 | Maintains | Strong Buy |
| 07/12/2022 | 21.6% | JP Morgan | $40.5 → $38 | Maintains | Neutral |
| 06/17/2022 | -13.6% | Wells Fargo | → $27 | Downgrades | Equal-Weight → Underweight |
| 04/13/2022 | 24.8% | JP Morgan | $49 → $39 | Maintains | Neutral |
| 03/10/2022 | 56.8% | JP Morgan | $66 → $49 | Maintains | Neutral |
| 11/08/2021 | 146.4% | Raymond James | $79 → $77 | Maintains | Strong Buy |
| 10/14/2021 | 111.2% | JP Morgan | → $66 | Downgrades | Overweight → Neutral |
| 08/19/2021 | 152.8% | Raymond James | $80 → $79 | Maintains | Strong Buy |
| 04/16/2021 | 108% | Wells Fargo | → $65 | Initiates Coverage On | → Equal-Weight |
| 03/16/2021 | — | Wolfe Research | Initiates Coverage On | → Peer Perform | |
| 03/12/2021 | 101.6% | B of A Securities | → $63 | Downgrades | Neutral → Underperform |
| 01/25/2021 | 127.2% | Raymond James | $61 → $71 | Maintains | Strong Buy |
| 01/05/2021 | — | B of A Securities | Downgrades | Buy → Neutral | |
| 10/30/2020 | 47.2% | Wells Fargo | → $46 | Upgrades | Underweight → Equal-Weight |
| 10/08/2020 | 114.4% | JP Morgan | → $67 | Upgrades | Neutral → Overweight |
| 09/15/2020 | 82.4% | B of A Securities | → $57 | Upgrades | Neutral → Buy |
| 07/29/2020 | 60% | JP Morgan | $38.5 → $50 | Maintains | Neutral |
| 07/29/2020 | 95.2% | Evercore ISI Group | → $61 | Upgrades | In-Line → Outperform |
| 06/05/2020 | 18.4% | Evercore ISI Group | → $37 | Downgrades | Outperform → In-Line |
| 04/09/2020 | 12% | Raymond James | $52 → $35 | Reiterates | → Strong Buy |
| 03/18/2020 | -29.6% | JP Morgan | $46.5 → $22 | Maintains | Neutral |
| 01/31/2020 | 34.4% | Wells Fargo | $39 → $42 | Downgrades | Equal-Weight → Underweight |
| 09/13/2019 | 31.2% | Wedbush | $35 → $41 | Maintains | Neutral |
| 09/13/2019 | 56.8% | Raymond James | $42 → $49 | Upgrades | Outperform → Strong Buy |
| 08/01/2019 | 12% | Wedbush | $30 → $35 | Reiterates | → Neutral |
| 11/12/2018 | 2.4% | Wedbush | $31 → $32 | Maintains | Neutral |
| 11/02/2018 | -0.8% | Wedbush | $34 → $31 | Maintains | Neutral |
| 10/25/2018 | -0.8% | Evercore ISI Group | $33 → $31 | Upgrades | In-Line → Outperform |
| 09/21/2018 | 2.4% | JP Morgan | $38 → $32 | Downgrades | Neutral → Underweight |
| 08/02/2018 | 8.8% | Wedbush | $33 → $34 | Maintains | Neutral |
| 08/02/2018 | — | B of A Securities | Upgrades | Underperform → Buy | |
| 07/13/2018 | — | JP Morgan | Upgrades | Underweight → Neutral | |
| 05/08/2018 | 24.8% | Raymond James | $35 → $39 | Maintains | Outperform |
| 05/04/2018 | — | Zelman | Upgrades | Hold → Buy | |
| 03/20/2018 | -4% | Wedbush | → $30 | Initiates Coverage On | → Neutral |
| 03/13/2018 | — | UBS | Upgrades | Sell → Buy | |
| 02/13/2018 | — | Raymond James | Upgrades | Market Perform → Outperform | |
| 02/02/2018 | 8.8% | B of A Securities | $31 → $34 | Maintains | Underperform |
| 01/03/2018 | — | Evercore ISI Group | Upgrades | Underperform → In-Line |
What is the target price for M.D.C. Holdings (MDC)?
The latest price target for M.D.C. Holdings (NYSE: MDC) was reported by JP Morgan on November 22, 2022. The analyst firm set a price target for $28.00 expecting MDC to fall to within 12 months (a possible -10.40% downside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for M.D.C. Holdings (MDC)?
The latest analyst rating for M.D.C. Holdings (NYSE: MDC) was provided by JP Morgan, and M.D.C. Holdings downgraded their underweight rating.
When is the next analyst rating going to be posted or updated for M.D.C. Holdings (MDC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of M.D.C. Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for M.D.C. Holdings was filed on November 22, 2022 so you should expect the next rating to be made available sometime around November 22, 2023.
Is the Analyst Rating M.D.C. Holdings (MDC) correct?
While ratings are subjective and will change, the latest M.D.C. Holdings (MDC) rating was a downgraded with a price target of $27.00 to $28.00. The current price M.D.C. Holdings (MDC) is trading at is $31.25, which is out of the analyst's predicted range.